Proteus Digital Health

About Proteus Digital Health

Armed with more than 450 issued patents and led by some of the brightest minds in technology, pharmaceuticals and healthcare, we’ve invented Digital Medicine, a new category of pharmaceuticals that measures medication treatment effectiveness, helps physicians improve clinical outcomes and patients reach health goals. Together, with leading health systems and pharmaceutical companies, we’re bringing this new digital solution to healthcare providers, thereby increasing access to better insight, optimized therapies and lower costs.

Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets.

Andrew Thompson

Co-Founder, CEO

Andrew Thompson is co-founder, president and chief executive officer of Proteus Digital Health. His vision for Digital Medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone’s pocket.

Andrew serves on the World Economic Forum Technology Pioneers selection committee and he is also a Co-Founder and Board member of Summit Schools, a leading Charter High School organization with a unique digital platform.  Andrew is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies.

He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.

George Savage, M.D.

Co-Founder, Chief Medical Officer

George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.

George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering.

George holds a B.S. in biomedical engineering from Boston University, an M.D. from Tufts University School of Medicine, and an M.B.A. from Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California. George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley.

Mark Zdeblick, Ph.D.

Co-Founder, Chief Technologist

Mark Zdeblick is chief technologist and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of Redwood Microsystems.

Mark holds a B.S. in civil engineering and a B.A. in architecture, both from the University of Illinois, and an M.S. in aeronautics and astronautics and Ph.D. in electrical engineering from Stanford University.

Uneek Mehra

Chief Financial Officer

As Chief Financial Officer, Uneek is responsible for accounting, financial reporting, budgeting, business planning and forecasting. He is also responsible for the Facilities, IT and People teams. Prior to joining Proteus, Uneek had extensive experience in senior finance leadership roles with Novartis, IBM and Citibank. At Novartis, Uneek worked in roles with increasing responsibilities in the Corporate Finance, Commercial Finance, Corporate Business Development and Treasury departments across the US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business.

Uneek has a MBA in strategy and leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India.

David O'Reilly

Chief Platform Officer

David O’Reilly is chief platform officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to health care and biotechnology companies at L.E.K. Consulting.

David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.

Sean Handel

Senior Vice President Product

Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he lead product initiatives from an early stage through the company’s IPO and subsequent acquisition by athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.

Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.

Neela Paykel

Head of Legal Affairs and Compliance

Neela Paykel is head of legal affairs and compliance at Proteus Digital Health. Prior to joining Proteus, Neela was assistant general counsel and practice group leader at Genentech where she served as the lead attorney providing legal support to the managed markets business unit. She advised on a broad range of managed care, healthcare law, privacy, antitrust and FDA promotional issues. Prior to Genentech, Neela was at CVS Caremark serving as the lead counsel for health plan PBM business and was an Associate Counsel at Blue Shield.

Neela is a graduate of Illinois Wesleyan University with a Bachelor of Arts in International Business Administration and received her Juris Doctorate degree from George Washington University

Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets

Jonathan Symonds, CBE


Jon Symonds, CBE, is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-Executive Director of Genomics England. He serves on the boards of Tala Energy, Feliz Pharmaceuticals, Aetion Inc., and Mesoblast.

Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc.

Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman.

Shumeet Banerji, Ph.D.

Board Member

Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. In 2013, Dr. Banerji retired from Booz & Company Inc. having served as its founding Chief Executive Officer.

Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally. He serves on the Board of HP, Inc., Reliance Industries Limited, Proteus Digital Health, Inc., Felix Pharmaceuticals Private Limited, and Tala Energy Private Limited.

Dr. Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.

Regina Benjamin, MD, MBA 

Board Member

Dr. Regina Benjamin is the Founder and CEO of BayouClinic in Bayou La Batre, Alabama, and the Picayune Endowed Chair of Public Health Sciences at Xavier University of Louisiana.

She was the 18th United States Surgeon General (2009 – 2013).

Dr. Benjamin serves on the boards of Kaiser Foundation Health Plan and Hospitals, the largest U.S. health managed care organization, and of Ascension, the world’s largest faith-based health system. She also serves on the boards of Diplomat, ConvaTec, CPSI, Next Level Health, and 98point6.

Robert Epstein, M.D., M.S.

Board Member

Dr. Robert Epstein is the cofounder and CEO of Epstein Health, LLC, a life science strategic consulting firm serving clients in the United States and Europe. Previously, Dr. Epstein served as president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.

Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and currently serves on the board of directors of Illumina, Fate Therapeutics, Veracyte, and Mindstrong Health.

He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.

Frank Fischer

Board Member

Frank Fischer has more than 25 years of senior management experience in the medical device industry.

The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.

Mr. Fischer continues to serve on the boards of several privately held medical device companies, in addition to serving on the board of trustees of Epilepsy Foundation of America, Rensselaer Polytechnic Institute, and Babson College.

Alan J. Levy, Ph.D.

Board Member

Dr. Alan Levy is a venture partner with Frazier Healthcare Partners and has over 30 years of senior management experience in the medical device industry.

Dr. Levy serves on the board of Intuitive Surgical, a publicly held company, in addition to Chrono Therapeutics, AbyRx, Signum Surgical, and the Center for Infectious Disease Research.

Myrtle Potter

Board Member

Myrtle Potter is founder and CEO of Myrtle Potter and Company. A best-selling author, Ms. Potter has dedicated three decades to serving the healthcare needs of millions of consumers.

She serves on the board of Rite Aid Corp., Liberty Mutual Insurance Group, and Insmed, Inc., and is on the University of Chicago Board of Trustees. Ms. Potter was president and chief operating officer of Genentech, president at Bristol-Myers Squibb and a vice president at Merck.

Ryan Schwarz

Board Member

Ryan Schwarz serves as managing director of NaviMed Capital and has over 30 years of investment and financial experience in healthcare. Previously, Mr. Schwarz led the healthcare investing practice for The Carlyle Group’s U.S. Venture & Growth Capital Group, specializing in medical devices, medical technology and healthcare information technology.

Mr. Schwarz currently serves on the boards of Lucent Health Solutions, Argos Health, and ORN Healthcare.

Charles Songhurst

Board Member

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.

Mr. Songhurst serves on the boards of Rigetti, SafeGraph, and CodeFights. Previously, he ran corporate strategy for Microsoft and focused on partnering and M&A.

Joseph R. Swedish

Board Member

Joseph R. Swedish is Executive Chairman of Anthem Inc., a Fortune 50 company, and the nation’s leading health benefits provider.

Formerly, Swedish served as CEO for several major integrated healthcare delivery systems, including Trinity Health, Colorado’s Centura Health, and Hospital Corporation of America.

Swedish serves on numerous corporate and industry association boards, and joined the Proteus Board of Directors in February 2018. He received his bachelor’s degree from the University of North Carolina at Charlotte and his master’s degree in health administration from Duke University.

Immanuel Thangaraj

Board Member

Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.

With more than 15 years of experience in operations and venture capital, he currently serves on the boards of Acura Pharmaceuticals, Kona Medical, Inc., and Serene LLC.

Work for a leader
that's transforming the industry.

We are Proteus Digital Health, the driving force behind an entirely new category of therapy called Digital Medicine. Every day, our employees are blazing new trails at the intersection of pharmaceuticals, technology, software and healthcare. Our company is on the forefront of transformative change to the healthcare industry. We are searching for pioneers, problem-solvers and inquisitive minds to help realize our vision: to improve healthcare for everyone, everywhere. Do you want to work in a dynamic environment where you can grow personally as well as professionally? Then apply today to join the Proteus team.

Make a
in the world

"We are developing a product that is changing people's lives."

Jeff Wiley, Head of Product Management

At Proteus Digital Health, we are developing leading-edge technology that will revolutionize how healthcare is delivered. What does that mean for our associates? They are playing an active role in the evolution of modern healthcare. Whether you are a software engineer, a data analyst or a pharmaceutical expert, you can help develop and deliver solutions that enhance the quality of care for everyone:

  • Patients get back on track
  • Physicians get deeper insight into patient health
  • Healthcare systems can better measure, manage and improve the health of entire patient populations
for everyone

“We acknowledge hard work and celebrate success every chance we get.”

Priya Raval, Senior Designer, HFE and User Research.

Proteus Digital Health is a company like no other, offering the discipline of a healthcare leader and the mentality of a tech innovator. Every week, our associates are taking on challenges and solving problems. As a company on the leading edge, we’re searching for a unique type of employee — someone with an entrepreneurial mindset and a can-do spirit who enjoys working in a fast-paced environment. We offer:

  • Personal development — there’s always an opportunity to learn and grow.
  • Entrepreneurial spirit — as an industry pioneer, we are constantly paving new ground.
  • Team mentality — we promote a culture of collaboration and teamwork.
  • Dynamic working environment — every day is filled with new challenges and breakthroughs.

Upcoming Events

  • Digital Medicine: Creating a New Category of Pharmaceuticals

    Time: Wednesday, June 20
    Location: Genentech Hall, UCSF Mission Bay, San Francisco, CA
    Speaker: Andrew Thompson, President & Chief Executive Officer, Proteus Digital Health

  • Digital Medicines Can Help Physicians Go on Vacation

    Time: Tuesday, June 26, 3:15pm
    Location: ExCeL London, London, UK
    Speaker: Andrew Thompson, President & Chief Executive Officer, Proteus Digital Health

    Medicines that communicate with a patient’s mobile when swallowed are commercial products in the USA. In this presentation you will learn how they expand access, improve outcomes and reduce costs. Digital Medicines enable physicians to more effectively manage chronic conditions in community settings and ensure they use their time for their patients who most need help and for their families who most need love.

  • Transforming Care Models and business Models with Digital Medicines

    Time: Tuesday, June 26, 9:00am
    Location: San Jose McEnery Convention Center, San Jose, CA
    Speaker: David O’Reilly, Chief Platform Officer, Proteus Digital Health

    ABILIFY MYCITE, developed by Otsuka Pharmaceutical and Proteus Digital Health, represents the first new category of drug approved by FDA since 1982 and is a new way to treat patients living with severe mental illness. The product and the expanding digital medicine field it represents also signals the emergence of a new business model for the pharmaceutical industry, one based on the integration of medications with hardware, software, analytics and services as well as one directly linked to patient-specific outcomes as the measure of pharmaceutical value and pricing. David O’Reilly provides background and insights into the potential for digital medicine and the opportunities and challenges for the pipeline of products now being developed and commercialized in this field.

  • Social Impact by Design

    Time: Tuesday, June 26, 2:30pm
    Location: The St. Regis, San Francisco, CA
    Speaker: George Savage, Chief Medical Officer, Proteus Digital Health

    As technology and society are coming together in new ways, finding meaningful, scalable solutions to big global problems will require reaching across the boundaries of organizations and disciplines. How can design help maximize the benefits and minimize the risks of change? How can we design systems to give us the benefits of storing and crunching our data without risking privacy and security concerns? How can systems innovation help companies collaborate better with the public sector? And how can we design our business model and our company culture to improve its positive impact on society and help communities achieve inclusive growth and equitable progress?

  • Pharma’s Embrace Of Digital

    Time: Thursday, June 28, 2:30pm
    Location: The St. Regis, San Francisco, CA
    Speaker: Betsy Klein, VP, Customer Partnering, Proteus Digital Health; Yuri Maricich, M.D., M.B.A., Chief Medical Officer & Head of Clinical Development, Pear Therapeutics; Steve Rosenberg, Commercial Head of Digital Medicine, Otsuka Pharmaceutical Companies; Jeremy Sohn, Global Head of Digital Business Development & Licensing, Novartis

  • Diving into Data Security and Privacy

    Time: Thursday, July 19, 10:30am
    Location: Hyatt Regency McCormick Place, Chicago, IL
    Speaker: Neela Paykel, VP, Head of Legal & Compliance, Proteus Digital Health; Lisa Pierce Reisz, Partner, Vorys, Sater, Seymour and Pease LLP; Kari Rollins, Partner, Sheppard, Mullin, Richter & Hampton LLP

    This presentation will cover: establishing and maintaining current compliance and risk management programs; Identifying risks, resisting cyber attacks, and preventing unauthorized access and ransomware data lockup; Review of most recent major data breaches and best preventive measures; Update on FTC’s enforcement initiatives; Intersection between HIPAA, electronic health records (“EHRs”), and the health information exchange (“HIE”); GDPR, related international privacy concerns, and imposing proper contracts on suppliers; Checklist for in-house health counsel.

Press Releases

News Stories

Press Office

For product images, video footage and interview requests, please contact the Proteus Press Office. Media requests only.

Phone Press. +1.650.637.6225

Our Partners

We have engaged license agreements with strategic partners to build our patented ingestible-sensor technology into new Digital Medicine offerings.


Otsuka and Proteus have combined Otsuka’s ABILIFY® (aripiprazole) with the FDA-cleared Proteus® ingestible sensor, embedding the sensor in single tablets at point of manufacture. The FDA granted its first approval of a Digital Medicine, ABILIFY MYCITE® (aripiprazole tablets with sensor), on November 13, 2017. ABILIFY MYCITE® is a drug -device combination product of Otsuka’s aripiprazole, an atypical antipsychotic, embedded with Proteus’ ingestible sensor that communicates with Proteus’ wearable sensor patch, and a smartphone application. The product measures ingestion of ABILIFY MYCITE® and patient activity, rest and mood. Otsuka’s first Digital Medicine provides an objective measure of medication-taking patterns of ABILIFY MYCITE® to help enhance collaboration with healthcare providers, who treat patients with certain serious mental illnesses.


Proteus has had a strategic partnership with Novartis since 2009.

Contact Us

For general inquiries regarding Proteus or our products:

Proteus Digital Health, Inc.
2600 Bridge Parkway
Redwood City, CA 94065
3956 Point Eden Way
Hayward, CA 94545